Skip to main content

Mucositis

7
Pipeline Programs
7
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
7
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Tosk
ToskCA - Mountain View
3 programs
3
TK-112690Phase 21 trial
TK-112690Phase 21 trial
TK-112690Phase 21 trial
Active Trials
NCT05669521Unknown24Est. Sep 2023
NCT05658016Unknown24Est. Sep 2023
NCT04046250Completed22Est. Mar 2020
Moberg Pharma
Moberg PharmaSweden - Stockholm
1 program
1
BupivacainePhase 21 trial
Active Trials
NCT02252926Completed70Est. Dec 2015
Autonomous Therapeutics
1 program
1
Doxycycline hyclatePhase 21 trial
Active Trials
NCT01087476Unknown164Est. Feb 2013
Biomed
BiomedAustralia - Sydney
1 program
1
TempolPhase 21 trial
Active Trials
NCT03480971Recruiting120Est. Dec 2025
Matrix Biomed
Matrix BiomedCA - Irvine
1 program
1
TempolPhase 2
Providence Therapeutics
1 program
Whole Food InterventionPHASE_1_21 trial
Active Trials
NCT02575313Terminated10Est. Sep 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ToskTK-112690
ToskTK-112690
ToskTK-112690
BiomedTempol
Moberg PharmaBupivacaine
Autonomous TherapeuticsDoxycycline hyclate
Providence TherapeuticsWhole Food Intervention

Clinical Trials (7)

Total enrollment: 434 patients across 7 trials

NCT05658016ToskTK-112690

Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690

Start: Jun 2022Est. completion: Sep 202324 patients
Phase 2Unknown
NCT05669521ToskTK-112690

Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690

Start: Jun 2022Est. completion: Sep 202324 patients
Phase 2Unknown
NCT04046250ToskTK-112690

Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690

Start: May 2019Est. completion: Mar 202022 patients
Phase 2Completed
NCT03480971BiomedTempol

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Start: May 2019Est. completion: Dec 2025120 patients
Phase 2Recruiting
NCT02252926Moberg PharmaBupivacaine

Local Anesthetic Treatment of Oral Pain in Patients With Mucositis

Start: Sep 2014Est. completion: Dec 201570 patients
Phase 2Completed
NCT01087476Autonomous TherapeuticsDoxycycline hyclate

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Start: May 2010Est. completion: Feb 2013164 patients
Phase 2Unknown
NCT02575313Providence TherapeuticsWhole Food Intervention

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer

Start: Oct 2009Est. completion: Sep 201210 patients
Phase 1/2Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 434 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.